Literature DB >> 21722291

Evaluating the utility of a preoperative nomogram for predicting 90-day mortality following radical cystectomy for bladder cancer.

Jennifer M Taylor1, Andrew Feifer, Caroline J Savage, Alexandra C Maschino, Melanie Bernstein, Harry W Herr, S Machele Donat.   

Abstract

OBJECTIVE: To evaluate the performance of the Isbarn nomogram for predicting 90-day mortality following radical cystectomy in a contemporary series. PATIENTS AND METHODS: We identified 1141 consecutive radical cystectomy patients treated at our institution between 1995 and 2005 with at least 90 days of follow-up. We applied the published nomogram to our cohort, determining its discrimination, with the area under the receiver operating characteristic curve (AUC), and calibration. We further compared it with a simple model using age and the Charlson comorbidity score.
RESULTS: Our cohort was similar to that used to develop the Isbarn nomogram in terms of age, gender, grade and histology; however, we observed a higher organ-confined (≤pT2, N0) rate (52% vs 24%) and a lower overall 90-day mortality rate [2.8% (95% confidence interval 1.9%, 3.9%) vs 3.9%]. The Isbarn nomogram predicted individual 90-day mortality in our cohort with moderate discrimination [AUC 73.8% (95% confidence interval 64.4%, 83.2%)]. In comparison, a model using age and Charlson score alone had a bootstrap-corrected AUC of 70.2% (95% confidence interval 67.2%, 75.4%).
CONCLUSIONS: The Isbarn nomogram showed moderate discrimination in our cohort; however, the exclusion of important preoperative comorbidity variables and the use of postoperative pathological stage limit its utility in the preoperative setting. The use of a simple model combining age and Charlson score yielded similar discriminatory ability and underscores the significance of individual patient variables in predicting outcomes. An accurate tool for predicting postoperative morbidity/mortality following radical cystectomy would be valuable for treatment planning and counselling. Future nomogram design should be based on preoperative variables including individual risk factors, such as comorbidities.
© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2011        PMID: 21722291      PMCID: PMC3193901          DOI: 10.1111/j.1464-410X.2011.10391.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  23 in total

1.  Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases.

Authors:  M A Ghoneim; M M el-Mekresh; M A el-Baz; I A el-Attar; A Ashamallah
Journal:  J Urol       Date:  1997-08       Impact factor: 7.450

2.  The prognosis with untreated bladder tumors.

Authors:  G R PROUT; V F MARSHALL
Journal:  Cancer       Date:  1956 May-Jun       Impact factor: 6.860

3.  Identifying risk factors for potentially avoidable complications following radical cystectomy.

Authors:  Brent K Hollenbeck; David C Miller; David Taub; Rodney L Dunn; Shukri F Khuri; William G Henderson; James E Montie; Willie Underwood; John T Wei
Journal:  J Urol       Date:  2005-10       Impact factor: 7.450

Review 4.  Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: an overview.

Authors:  Emil Scosyrev; James Messing; Katia Noyes; Peter Veazie; Edward Messing
Journal:  Urol Oncol       Date:  2010-04-03       Impact factor: 3.498

5.  Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma.

Authors:  Vincenzo Ficarra; Orietta Dalpiaz; Najati Alrabi; Giacomo Novara; Antonio Galfano; Walter Artibani
Journal:  BJU Int       Date:  2005-04       Impact factor: 5.588

6.  Analysis of early complications after radical cystectomy: results of a collaborative care pathway.

Authors:  Sam S Chang; Michael S Cookson; Roxelyn G Baumgartner; Nancy Wells; Joseph A Smith
Journal:  J Urol       Date:  2002-05       Impact factor: 7.450

7.  Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.

Authors:  Joseph A Mitchell; Matthew R Cooperberg; Eric P Elkin; Deborah P Lubeck; Shilpa S Mehta; Christopher J Kane; Peter R Carroll
Journal:  J Urol       Date:  2005-04       Impact factor: 7.450

8.  A critical analysis of perioperative mortality from radical cystectomy.

Authors:  Marcus L Quek; John P Stein; Siamak Daneshmand; Gus Miranda; Duraiyah Thangathurai; Peter Roffey; Eila C Skinner; Gary Lieskovsky; Donald G Skinner
Journal:  J Urol       Date:  2006-03       Impact factor: 7.450

9.  Assessing comorbidity using claims data: an overview.

Authors:  Carrie N Klabunde; Joan L Warren; Julie M Legler
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

Review 10.  An electronic application for rapidly calculating Charlson comorbidity score.

Authors:  William H Hall; Ramanathan Ramachandran; Samir Narayan; Ashesh B Jani; Srinivasan Vijayakumar
Journal:  BMC Cancer       Date:  2004-12-20       Impact factor: 4.430

View more
  5 in total

1.  Cancer and All-cause Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy: Development and Validation of a Nomogram for Treatment Decision-making.

Authors:  Stephen B Williams; Jinhai Huo; Yiyi Chu; Jacques G Baillargeon; Timothy Daskivich; Yong-Fang Kuo; Christopher D Kosarek; Simon P Kim; Eduardo Orihuela; Douglas S Tyler; Stephen J Freedland; Ashish M Kamat
Journal:  Urology       Date:  2017-08-25       Impact factor: 2.649

2.  Comorbidity and nutritional indices as predictors of morbidity after transurethral procedures: A prospective cohort study.

Authors:  Massimo Valerio; Yannick Cerantola; Urs Fritschi; Martin Hubner; Katia Iglesias; Anne-Sophie Legris; Ilaria Lucca; Yannis Vlamopoulos; Laurent Vaucher; Patrice Jichlinski
Journal:  Can Urol Assoc J       Date:  2014-09       Impact factor: 1.862

3.  Is extended pharmacologic venous thromboembolism prophylaxis uniformly safe after radical cystectomy?

Authors:  Reza Mehrazin; Zachary Piotrowski; Brian Egleston; Daniel Parker; Jeffrey J Tomaszweski; Marc C Smaldone; Philip H Abbosh; Timothy Ito; Paul Bloch; Kevan Iffrig; Marijo Bilusic; David Y T Chen; Rosalia Viterbo; Richard E Greenberg; Robert G Uzzo; Alexander Kutikov
Journal:  Urology       Date:  2014-10-24       Impact factor: 2.649

Review 4.  A systematic review of the tools available for predicting survival and managing patients with urothelial carcinomas of the bladder and of the upper tract in a curative setting.

Authors:  Sarah J Drouin; David R Yates; Vincent Hupertan; Olivier Cussenot; Morgan Rouprêt
Journal:  World J Urol       Date:  2012-12-18       Impact factor: 4.226

5.  Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients.

Authors:  Stephen B Williams; Ashish M Kamat; Karim Chamie; Michael Froehner; Manfred P Wirth; Peter N Wiklund; Peter C Black; Gary D Steinberg; Stephen A Boorjian; Sia Daneshmand; Peter J Goebell; Kamal S Pohar; Shahrokh F Shariat; George N Thalmann
Journal:  Eur Urol Oncol       Date:  2018-06-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.